Introduction
CIPN, breast cancer
SIDE EFFECT, BREAST CANCER, ONCOLOGY, EFFECTS OF CHEMOTHERAPY, CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and potentially debilitating side effect of chemotherapy agents such as platinum agents, taxanes, vinca alkaloids, and bortezomib.Despite the high incidence and debilitating symptoms of CIPN, the American Society of Clinical Oncology (ASCO) 2020 CIPN guideline recommends that, during chemotherapy, the main intervention is chemotherapy dose reduction or discontinuation due to a lack of evidence of any effective CIPN prevention approaches.Additional treatment to reduce CIPN symptoms is needed and further emphasize the importance of CIPN prevention. Our group conducted a phase IIA trial that showed weekly acupuncture may be effective in preventing the progression of CIPN severity. In this retrospective study of this trial, we analyzed baseline characteristics associated with CIPN onset and progression during weekly paclitaxel in women with ­early-stage breast cancer to identify potentially modifiable risk factors that increase the risk of CIPN during chemotherapy, and to examine the effects of chemotherapy dose reduction on breast cancer-specific outcome.